3-苄基咪唑烷-1-羧酸叔丁酯 | 623943-75-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-苄基咪唑烷-1-羧酸叔丁酯
• 英文名称: tert-butyl 3-benzylimidazolidine-1-carboxylate
• CAS: 623943-75-9
• 化学式: C₁₅H₂₂N₂O₂
• 分子量: 262.352
• InChiKey: OSIWDWJGKVEDRT-UHFFFAOYSA-N

物化性质

• 沸点：
  345.6±35.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-苄基咪唑烷-1-羧酸叔丁酯 在 磷酸 作用下， 以 四氢呋喃 为溶剂， 以98%的产率得到1-苄基咪唑烷
  参考文献：
  名称：

  Aqueous phosphoric acid as a mild reagent for deprotection of the t-butoxycarbonyl group

  摘要：

  Aqueous phosphoric acid (85 wt%) is an efficient and mild reagent for the deprotection of N-BOC groups. Acid sensitive functionalities including benzyl and methyl esters, TBDMS ether, CBZ and isopropylidene groups are compatible with the reaction conditions. The reactions are high yielding, and the workup is convenient. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2003.09.040
• 作为产物：
  描述：

  N-苄基乙二胺 在 magnesium sulfate 、 potassium carbonate 作用下， 以 氯仿 为溶剂， 反应 36.0h， 生成 3-苄基咪唑烷-1-羧酸叔丁酯
  参考文献：
  名称：

  Preparation of diamines by lithiation–substitution of imidazolidines and pyrimidines

  摘要：

  通过未取代的二胺合成手性1,2-二胺和1,3-二胺的方法是，先使二胺与N-叔丁氧羰基（Boc）取代的咪唑啉（四氢咪唑）或嘧啶（六氢-1,3-二嗪）反应，再用仲丁基锂处理，使α位上的氢原子去质子化并与N-Boc基团反应，接着加入亲电试剂得到取代产物，后者在酸性条件下水解后可得到取代的1,2-或1,3-二胺。使用手性配体（-）-鹰爪豆碱能促进咪唑啉底物的非对称去质子化，水解后得到旋光纯度较高的1,2-二胺。

  DOI：

  10.1039/b301502e

文献信息

• [EN] HEPATITIS B VIRAL ASSEMBLY EFFECTORS<br/>[FR] EFFECTEURS D'ASSEMBLAGE DE VIRUS DE L'HÉPATITE B
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2016168619A1

  公开（公告）日：2016-10-20

  Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

  揭示了一种对乙型肝炎病毒（HBV）感染具有治疗效果的新型组装效应子化合物。本文描述的组装效应子分子可以导致病毒组装缺陷，也可能影响与慢性HBV感染相关的其他病毒活动。还公开了一种合成所述化合物的方法，通过给予所述化合物治疗HBV的方法，以及利用这些化合物制造针对HBV的药物的用途。
• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• [EN] KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT<br/>[FR] INHIBITEURS DE KINASE ET MÉTHODES DE SYNTHÈSE ET TRAITEMENT
  申请人：INSILICO MEDICINE IP LTD

  公开号：WO2021038419A1

  公开（公告）日：2021-03-04

  Compounds that function as kinase inhibitors are provided. The kinase inhibitors can have any structure of the formulae provided herein, such as shown for Compounds 1-4. A pharmaceutical composition can include: the compound of one of the embodiments; and a pharmaceutically acceptable carrier having the compound. A method of inhibiting a kinase can include: providing the compound of one of the embodiments described herein to the kinase such that the kinase is inhibited. The methods can include inhibiting DDR1 and/or DDR2, and thereby providing a modulation or decrease in the activity of DDR1 and/or DDR2. This decrease in DDR1 and/or DDR2 activity can be used as therapy to treat conditions related to DDR1 and/or DDR2 activity, such as fibrosis, cancer, and others.

  提供作为激酶抑制剂的化合物。激酶抑制剂可以具有此处提供的任何结构的化学式，例如所示的化合物1-4。药物组合物可以包括：其中一种实施例的化合物；以及具有该化合物的药学上可接受的载体。抑制激酶的方法可以包括：将此处描述的其中一种实施例的化合物提供给激酶，从而抑制激酶。这些方法可以包括抑制DDR1和/或DDR2，从而调节或减少DDR1和/或DDR2的活性。减少DDR1和/或DDR2活性可用作治疗与DDR1和/或DDR2活性相关的疾病，如纤维化、癌症等。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。
• Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
  申请人：Griffioen Gerard

  公开号：US08618138B2

  公开（公告）日：2013-12-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物及其用作药物的新型化合物，更具体地用于预防或治疗神经退行性疾病，更具体地用于某些神经系统疾病，如被称为tau病变的疾病和由细胞毒性α-突触核蛋白淀积引起的疾病。本发明还涉及使用所述新型化合物制备用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的制药组合物以及制备所述新型化合物的方法。